Aspira Pathlab & Diagnostics Ltd — Important, 01-01-1970: Company Update

Acquirers and a PAC have launched an open offer to acquire 2.68 Cr equity shares of Aspira Pathlab & Diagnostics, representing 26% of the company, at ₹55 per share. The company's Independent Directors deem the offer price fair and reasonable for public shareholders. Financial results for the quarter and half-year, updated for the period ending December 31, 2025, show income from operations at ₹18.46 Cr and profit after tax at ₹0.74 Cr. Notably, some Acquirers and PACs were reclassified to the Promoter/Promoter Group. No statutory approvals are required for the offer, and no shares are currently locked-in. The tendering process will occur through a Stock Exchange Mechanism.